Related Experiment Video
Updated: Jul 27, 2026
06:51
Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration
Published on: June 7, 2012
Estrogen replacement therapy and Alzheimer's disease
1Department of Pharmacology, Chemical Pharmaceutical Research Institute, Sofia, Bulgaria.
Drugs of Today (Barcelona, Spain : 1998)
|January 27, 2004
Summary
Estrogen replacement therapy (ERT) may improve cognitive function and reduce Alzheimer's disease (AD) risk in postmenopausal women. Further clinical trials are needed to confirm ERT's efficacy for AD prevention and treatment.
Area of Science:
- Neuroscience
- Endocrinology
- Gerontology
Background:
- Estrogen replacement therapy (ERT) offers benefits for postmenopausal women, including cardiovascular and bone health.
- Retrospective studies suggest ERT may reduce Alzheimer's disease (AD) risk and slow progression.
- Recent clinical data indicate cognitive improvements in women with AD undergoing ERT.
Purpose of the Study:
- To explore the potential of ERT in managing cognitive function in postmenopausal women.
- To investigate the role of estrogen in Alzheimer's disease pathogenesis and treatment.
- To summarize evidence on ERT's effects on cognitive decline and AD.
Main Methods:
- Review of retrospective epidemiological studies on ERT and AD risk.
- Analysis of recent clinical studies assessing cognitive function in women with AD.
- Examination of basic science findings on estrogen's mechanisms of action in the brain.
Main Results:
- ERT is associated with a potential reduction in AD risk and delayed progression.
- Clinical studies show ERT can improve cognitive functions in women diagnosed with AD.
- Estrogen's neuroprotective mechanisms include cholinergic system interaction, neurotrophic effects, and anti-amyloid activity.
Conclusions:
- Estrogen therapy presents a potential strategy for enhancing cognitive function in postmenopausal women, both with and without dementia.
- ERT may help delay the onset and progression of Alzheimer's disease.
- Prospective clinical trials are essential to validate the efficacy of ERT for AD prevention and treatment.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...